Relapse after glofitamab has a poor prognosis and rates of <scp>CD20</scp> loss are high
Sam Grigg, Adrian Minson, Elizabeth Prins, Michael Dickinson
Abstract
We reviewed cases with aggressive B-cell non-Hodgkin lymphoma who relapsed or progressed following glofitamab. The prognosis was poor, with low rates of response to subsequent salvage therapies, and a median overall survival of 4.1 months from the time of progression. There were high rates of CD20 loss (59%) at the time of relapse. In a field where CD20 × CD3 bispecific antibodies are entering routine clinical use, our experience highlights a potential means of resistance. It illustrates both the need to further characterise mechanisms of CD20 loss, and to pursue clinical trials of novel non-CD20-directed treatments in this cohort.
Topics & Concepts
MedicineCD20LymphomaOncologyInternal medicineClinical trialCohortImmunologyLymphoma Diagnosis and TreatmentCAR-T cell therapy researchChronic Lymphocytic Leukemia Research